152 related articles for article (PubMed ID: 11052148)
1. European best practice guidelines 14-16: inadequate response to epoetin.
Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Thompson K; Carveth BG
Nephrol Dial Transplant; 2000; 15 Suppl 4():43-50. PubMed ID: 11052148
[No Abstract] [Full Text] [Related]
2. European best practice guidelines 9-13: anaemia management.
Jacobs C; Hörl WH; Macdougall IC; Valderrábano F; Parrondo I; Abraham IL; Segner A
Nephrol Dial Transplant; 2000; 15 Suppl 4():33-42. PubMed ID: 11052147
[No Abstract] [Full Text] [Related]
3. European best practice guidelines 6-8: assessing and optimizing iron stores.
Macdougall IC; Hörl WH; Jacobs C; Valderrábano F; Parrondo I; Thompson K; Cremers S
Nephrol Dial Transplant; 2000; 15 Suppl 4():20-32. PubMed ID: 11052146
[No Abstract] [Full Text] [Related]
4. European best practice guidelines 1-4: evaluating anaemia and initiating treatment.
Valderrábano F; Hörl WH; Jacobs C; Macdougall IC; Parrondo I; Cremers S; Abraham IL
Nephrol Dial Transplant; 2000; 15 Suppl 4():8-14. PubMed ID: 11052144
[No Abstract] [Full Text] [Related]
5. [Therapeutic guidelines for renal anemia in Japan].
Naito M; Akiba T
Nihon Rinsho; 2004 Jun; 62 Suppl 6():562-5. PubMed ID: 15250369
[No Abstract] [Full Text] [Related]
6. Our experience with epoetins in treating renal anemia.
Bren A; Kandus A
Ther Apher Dial; 2005 Jun; 9(3):202-4. PubMed ID: 15966988
[TBL] [Abstract][Full Text] [Related]
7. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
8. Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study.
Pajek J; Bucar-Pajek M; Grego K; Gucek A; Bevc S; Ekart R; Vujkovac B; Golob-Kosmina P; Kandus A; Bren AF
Ther Apher Dial; 2005 Jun; 9(3):228-32. PubMed ID: 15966995
[TBL] [Abstract][Full Text] [Related]
9. Target hemoglobin level for EPO therapy in CKD.
Parfrey PS
Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
[No Abstract] [Full Text] [Related]
10. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
11. European best practice guidelines 17-18: adverse effects.
Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Carveth BG; Thompson K
Nephrol Dial Transplant; 2000; 15 Suppl 4():51-6. PubMed ID: 11052149
[No Abstract] [Full Text] [Related]
12. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
13. Anemia in renal insufficiency.
Santoro A
Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
[TBL] [Abstract][Full Text] [Related]
14. The EPO/iron marriage: counseling needed.
Bralow S
Nephrol News Issues; 2007 Jun; 21(7):53, 55. PubMed ID: 17623987
[No Abstract] [Full Text] [Related]
15. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
16. European best practice guidelines 5: target haemoglobin.
Jacobs C; Hörl WH; Macdougall IC; Valderrábano F; Parrondo I; Segner A; Abraham IL
Nephrol Dial Transplant; 2000; 15 Suppl 4():15-9. PubMed ID: 11052145
[No Abstract] [Full Text] [Related]
17. [Stability of hemoglobin levels: an indispensible paradigm change in medical management].
Zaoui P; Deray G; Ortiz JP; Rostaing L
Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H5-7. PubMed ID: 21371678
[No Abstract] [Full Text] [Related]
18. [Hyporesponsiveness to recombinant human erythropoietin therapy in anemic patients on hemodialysis].
Maeda H; Hirakata H
Nihon Rinsho; 2004 Jun; 62 Suppl 6():307-11. PubMed ID: 15250314
[No Abstract] [Full Text] [Related]
19. Individualizing anaemia treatment: a discussion of case histories.
Muirhead N
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826
[TBL] [Abstract][Full Text] [Related]
20. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
